Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 9/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 8/20 | 0.42 |
| ▸ | CA7 | P43166 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31700562 | 1.00 | STS (0.50) | STSCA2CA9CA12CA1 | |
| SCHEMBL28232625 | 0.87 | STS (0.61) | STSCA2CA9CA12CA1 | |
| SCHEMBL12988638 | 0.84 | CA2 (0.40) | STSCA2CA9CA12CA1 | |
| SCHEMBL27798617 | 0.83 | STS (0.43) | STSCA2CA9CA12CA1 | |
| SCHEMBL4739311 | 0.83 | STS (0.43) | STSCA2CA9CA12CA1 | |
| SCHEMBL11506043 | 0.83 | STS (0.43) | STSCA2CA9CA12CA1 | |
| SCHEMBL12988457 | 0.75 | CA2 (0.46) | STSCA2CA9CA12CA1 | |
| SCHEMBL12989492 | 0.75 | CA2 (0.46) | STSCA2CA9CA12CA1 | |
| SCHEMBL4483680 | 0.73 | PHGDH (0.38) | STSCYP2B6RAB9ANPC1LMNA | |
| SCHEMBL6957005 | 0.73 | CA1 (0.44) | STSCA2CA9CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105705489-B | Compound as immunomodulator | 百时美施贵宝公司 | 2019-04-26 | — | — | CN | claimed |
| CN-108884093-A | 6,7,8,9- tetrahydro -5H- pyrido [2,3-d] azepine * dopamine D 3 ligands | 辉瑞公司 | 2018-11-23 | — | — | CN | claimed |
| CN-108383828-A | 1 new, 2- as chemokine receptor modulators is bis--sulfamide derivative | 阿勒根公司 | 2018-08-10 | — | — | CN | claimed |
| US-20250319056-A1 | METHODS FOR TREATING CANCER | UNIV INDIANA TRUSTEES (US) | 2025-10-16 | — | — | US | disclosed |
| CN-105705489-B | Compound as immunomodulator | 百时美施贵宝公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-108884093-A | 6,7,8,9- tetrahydro -5H- pyrido [2,3-d] azepine * dopamine D 3 ligands | 辉瑞公司 | 2018-11-23 | — | — | CN | disclosed |
| EP-3402796-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS | Pfizer Inc (US) | 2018-11-21 | — | — | EP | disclosed |
| CN-108383828-A | 1 new, 2- as chemokine receptor modulators is bis--sulfamide derivative | 阿勒根公司 | 2018-08-10 | — | — | CN | disclosed |
| WO-2017122116-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS | PFIZER INC. (US) | 2017-07-20 | — | — | WO | disclosed |
| WO-2007014273-A2 | SULFONAMIDES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070021495-A1 | SULFONAMIDES AS SELECTIVE ESTROGEN RECEPTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-25 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| CN-1077888-C | Benzopyrans and pharmaceutical compositions containing them | NOVARTIS AG (CH) | 2002-01-16 | — | — | CN | disclosed |
| EP-0828733-B1 | BENZOPYRANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NOVARTIS AG (CH) | 2001-09-05 | — | — | EP | disclosed |
| US-5905156-A | POTASSIUM CHANNEL ACTIVATORS AND BRONCHODILATORS | NOVARTIS AG (CH) | 1999-05-18 | — | — | US | disclosed |
| US-5869478-A | ADMINISTERING AS ANTIISCHEMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| CN-1185153-A | Benzopyrans and pharmaceutical composition contg. same | CIBA GEIGY AG (CH) | 1998-06-17 | — | — | CN | disclosed |
| EP-0828733-A1 | BENZOPYRANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Novartis AG (CH) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996037490-A1 | BENZOPYRANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NOVARTIS AG (CH) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021495-A1 | SULFONAMIDES AS SELECTIVE ESTROGEN RECEPTOR | ESR1, ESR2, GPER1 | STS 25/4885CA2 952/4885CA9 2114/4885 |
| US-20250319056-A1 | METHODS FOR TREATING CANCER | HSP90AB1, HSP90B1, HSP90AB2P | STS 4333/4885CA2 2002/4885CA9 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.